A linear regression analysis between the single-plex and 3-plex assays is shown in Fig. 4B, yielding an R2 value ≥ 0.98 for all 3 biomarkers. To show the specificity of this metric, a linear regression between 3-plex measurements of GDF15 and p53 autoantibody,

in which no correlation is expected, yields an R2 value of 0.04. Finally, in a culmination of these efforts, the learn more full 3-plex assay was performed on 186 CRC and normal patient serum/plasma samples (59 normal and 127 CRC) (Fig. 5A). Using the aforementioned cutoff and scoring method, individually, CEA, GDF15 and the p53 TAA were 21%, 38% and 11% sensitive and 98%, 100% and 100% specific, respectively. Composite sensitivity and specificity of all 3 biomarkers in the multiplexed assay were 54% and 98%, respectively and biomarker overlap (or lack thereof) is shown in the Venn Diagram in Fig. 5B. Notably, while partial redundancy is observed, each biomarker detects several CRC patients that the other biomarkers do not (9, 11 and 29 unique patients for p53, CEA and GDF15, respectively). Here we demonstrate the novel adaptation of Illumina’s multiplexed, genomic, VeraCode™ micro-bead technology for high-throughput immunoassay and validation of two classes of serological biomarkers: autoantibodies to TAAs (see AZD0530 solubility dmso Fig. 1)

and circulating non-antibody proteins, using colorectal cancer (CRC) as a model system. We have created a multiplexed “hybrid” assay for Pyruvate dehydrogenase the simultaneous detection of these two classes of serological biomarkers. To our knowledge, this is the first report of use of the VeraCode™ micro-beads

as a protein/immunoassay platform. The potential advantages of this assay include its requirement for only a small volume of blood, the ability to multiplex and perform this in a high-throughput manner, and the ability to add in new biomarkers to eventually achieve a higher level of sensitivity while maintaining a high specificity for CRC diagnosis. Our goal is to continue to add to and refine our 3-marker CRC panel, thereby creating an effective CRC diagnostic screening test, which would be predicted to have excellent compliance due to its non-invasive nature. This approach could be used as a targeted population-wide screening test (for people over 50), or could eventually replace the colonoscopy altogether, assuming that the appropriate level of sensitivity and specificity is achieved by the expansion of our CRC biomarker panel. Another use for this novel protein-based platform could be for the high-throughput clinical validation studies which are urgently needed for the constant stream of newly reported putative serological biomarkers.